arrow
A

Anna Nappi

universita della campania vanvitelli
H指数:22
被引数:1,895

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Value of Baseline [18F]FDG-PET in Predicting the Progression-Free Survival in Patients with Thymic Epithelial Tumours: A Systematic Review and Meta-Analysis

基线[18F]FDG-PET在预测胸腺上皮肿瘤患者无进展生存期中的价值:一项系统评价和Meta分析

2025-09-290
OAAI
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study

Regorafenib单药治疗RAS突变型晚期结直肠癌 (STREAM) 患者的二线治疗: 一项学术,多中心,单臂,两阶段,II期研究

2023-02-012
OAAI
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study
2022-06-010
OA
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

阿柏西普或贝伐单抗联合FOLFIRI作为mRAS转移性结直肠癌患者的二线治疗: 仲裁研究方案

2021-03-2411
OAAI
Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial
2020-12-010
PREAI
Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
2020-09-0117
OAAI
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol
2020-08-1113
OAAI